SCHEMBL6437447

SCHEMBL6437447

CCOC(=O)N[C@H](Cc1ccc(OC)cc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.57
KMT2A Q03164 2/20 0.57
LDHA P00338 1/20 0.56
CA2 P00918 1/20 0.55
GLA P06280 1/20 0.55
ITGB3 P05106 7/20 0.53
ITGAV P06756 2/20 0.53
ATM Q13315 1/20 0.51
ITGA2B P08514 5/20 0.49
ALDH1A1 P00352 1/20 0.49
ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437450 1.00 FPR2 (0.57) FPR2KMT2ALDHACA2GLA
SCHEMBL7430458 1.00 FPR2 (0.57) FPR2KMT2ALDHACA2GLA
SCHEMBL10663117 0.88 LDHA (0.63) FPR2KMT2ALDHACA2ITGB3
SCHEMBL8765951 0.88 LDHA (0.63) FPR2KMT2ALDHACA2ITGB3
SCHEMBL8485515 0.88 FPR2 (0.54) FPR2KMT2ALDHACA2ITGB3
SCHEMBL2320402 0.88 FPR2 (0.54) FPR2KMT2ALDHACA2ITGB3
SCHEMBL9559418 0.86 FOLH1 (0.58) CA2ITGB3ITGAVITGA2B
SCHEMBL9559423 0.86 FOLH1 (0.58) CA2ITGB3ITGAVITGA2B
SCHEMBL3769914 0.85 L3MBTL1 (0.58) ITGB3ITGAVITGA2BALDH1A1ALOX15
SCHEMBL996293 0.85 L3MBTL1 (0.58) ITGB3ITGAVITGA2BALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505062-A1 Heterocyclic derivatives and their use as antithrombotic agents Akzo Nobel N.V. (NL) 2005-02-09 EP disclosed
US-6797710-B2 CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY AKZO NOBEL N.V. (NL) 2004-09-28 US disclosed
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents MERCK SHARP & DOHME B.V. (NL) 2003-07-10 US disclosed
US-6444672-B1 ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR AKZO NOBEL N.V. (NL) 2002-09-03 US disclosed
US-6432955-B1 ANTICOAGULANTS AKZO NOBEL N.V. (NL) 2002-08-13 US disclosed
US-6194409-B1 SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH AKZO NOBEL N.V. (NL) 2001-02-27 US disclosed
EP-0975600-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS Akzo Nobel N.V. (NL) 2000-02-02 EP disclosed
WO-1998047876-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS AKZO NOBEL N.V. (NL) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents F2, F12, VKORC1 FPR2 723/4885KMT2A 2507/4885LDHA 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.